Potential Biomarkers Associated with Pulmonary Vascular Disease

Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience

Azadeh Issapour, Benjamin Frank, Sarah Crook, Michelle D. Hite, Michelle L. Dorn, Erika B. Rosenzweig, D. Dunbar Ivy, Usha S. KrishnanColumbia University Irving Medical Center. University of Colorado and Children’s Hospital Colorado.United States Pediatric PulmonologyPediatr Pulmonol 2022; 57: 724-733DOI: 10.1002/ppul.25796 AbstractObjective: To describe the safety and tolerability of treatment with ambrisentan and tadalafil in pediatric pulmonary hypertension […]

Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience Read More »

Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation

Thomas R. Fleming, Christine E. Garnett, Laurie S. Conklin, Solange Corriol‑Rohou, Sudharshan Hariharan, Daphne Hsu, Guenther Mueller‑Velten, Yeruk Mulugeta, Ronald Portman, Mark D. Rothmann, Norman L. Stockbridge, Simon Wandel, Jialu Zhang, Lynne YaoUniversity of Washington. U.S. Food and Drug Administration. Janssen Research and Development. AstraZeneca. Children’s Hospital at Montefiore and Albert Einstein College of Medicine. Novartis Pharma AG and Novartis Pharmaceuticals.United States Therapeutic Innovation and Regulatory ScienceTher Innov Regul Sci 2023; 57: 109-120DOI: 10.1007/s43441-022-00445-6 AbstractEven with recent substantive improvements in health care in pediatric populations, considerable need remains

Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation Read More »

NT-proBNP and Zlog-transformed NT-proBNP values predict extubation failure in critically ill neonates with pulmonary hypertension and ventricular dysfunction

Lukas Schroeder, Manuel Kuelshammer, Ramona Dolsheid-Pommerich, Stefan Holdenrieder, Andreas Mueller, Florian KipfmuellerUniversity Children’s Hospital Bonn. University Hospital Bonn. Technical University Munich.Germany Pediatric PulmonologyPediatr Pulmonol 2023; 58: 253-261DOI: 10.1002/ppul.26193 AbstractObjectives: Critically ill neonates with a history of pulmonary hypertension (PH) or ventricular dysfunction are at risk to experience an extubation failure (EF) after liberation from mechanical ventilation (MV).

NT-proBNP and Zlog-transformed NT-proBNP values predict extubation failure in critically ill neonates with pulmonary hypertension and ventricular dysfunction Read More »

Computational platform for doctor-artificial intelligence cooperation in pulmonary arterial hypertension prognostication: a pilot study

Vitaly O. Kheyfets, Andrew J. Sweatt, Mardi Gomberg-Maitland, D. Dunbar Ivy, Robin Condliffe, David G. Kiely, Allan Lawrie, Bradley A. Maron, Roham T. Zamanian, Kurt R. StenmarkUniversity of Colorado. Stanford University. George Washington University. University of Sheffield. Harvard University.United States and United Kingdom Canadian Respiratory Journal Open ResearchCRJ Open Res 2023; 9: DOI: 10.1183/23120541.00484-2022 AbstractBackground: Pulmonary arterial

Computational platform for doctor-artificial intelligence cooperation in pulmonary arterial hypertension prognostication: a pilot study Read More »

Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review

Chantal Lokhorst, Sjoukje van der Werf, Rolf M. F. Berger, Johannes M. DouwesUniversity of Groningen, Beatrix Children’s Hospital and University Medical Center GroningenNetherlands Frontiers in Cardiovascular MedicineFront Cardiovasc Med 2022; 9: 1035453DOI: 10.3389/fcvm.2022.1035453 AbstractIntroduction: Currently, risk stratification is the cornerstone of determining treatment strategy for patients with pulmonary arterial hypertension (PAH). Since the 2015 European Society of

Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review Read More »

Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension

Megan Griffiths, Jun Yang, Dhananjay Vaidya, Melanie Nies, Stephanie Brandal, D. Dunbar Ivy, Francis Hickey, Kristine Wolter-Warmerdam, Eric D. Austin, Mary Mullen, Michael W. Pauciulo, Katie A. Lutz, Erika B. Rosenzweig, Russel Hirsch, Delphine Yung, William C. Nichols, Allen D. EverettJohns Hopkins University. University of Colorado and Children’s Hospital Colorado. Vanderbilt University. Harvard University and

Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension Read More »

Scroll to Top